
INCA33989 continues to show strong safety and early signs of disease modification in essential thrombocythemia, according to John Mascarenhas, MD, with next steps focused on optimizing dosing and delivery scheduling.
John Mascarenhas, MD, is the director of the Center of Excellence for Blood Cancers and Myeloid Disorders and a professor of medicine at the Icahn School of Medicine at Mount Sinai.
INCA33989 continues to show strong safety and early signs of disease modification in essential thrombocythemia, according to John Mascarenhas, MD, with next steps focused on optimizing dosing and delivery scheduling.
John Mascarenhas, MD, discusses phase 1 data showing that INCA33989 is a well-tolerated therapy for calreticulin–mutant essential thrombocythemia, with early signs of efficacy and potential disease modification.
John Mascarenhas, MD, discusses the rationale, mechanism, and design of the phase 1 INCA33989-101 and -102 trials investigating a CAL-R–targeted antibody for patients with essential thrombocythemia.
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.